Low incidence and prevalence of hepatitis C in two cohorts of HIV pre‐exposure prophylaxis adherence interventions in men who have sex with men in Southern California

Low incidence and prevalence of hepatitis C in two cohorts of HIV pre‐exposure prophylaxis adherence interventions in men who have sex with men in Southern California

HIV pre‐exposure prophylaxis (PrEP) has been associated with incident hepatitis C virus (HCV) infection in men who have sex with men (MSM) due to decreased condom use. We examined rates of HCV among MSM and transgender women at high‐risk of HIV on PrEP in Southern California using data from two tria...

Full description

Saved in:
Bibliographic Details
Published in:Journal of viral hepatitis Vol. 29; no. 7; pp. 529 - 535
Main Authors: Hassan, Adiba, Agustin, Harold Glenn San, Burke, Leah, Kofron, Ryan, Corado, Katya, Bolan, Robert, Landovitz, Raphael J., Dubé, Michael P., Morris, Sheldon R.
Format: Journal Article
Language:English
Published: England Wiley Subscription Services, Inc 01-07-2022
Subjects:
Clinical Trials as Topic
Disease prevention
Female
Hepacivirus
Hepatitis C
Hepatitis C - epidemiology
Hepatitis C - prevention & control
HIV
HIV Infections - epidemiology
HIV Infections - prevention & control
Homosexuality, Male
Human immunodeficiency virus
Humans
Incidence
Male
MSM (men who have sex with men)
Pharynx
Pre-Exposure Prophylaxis
PrEP
Prevalence
Prophylaxis
Sexual and Gender Minorities
Sexual Behavior
Substance use
Southern California
United States > US
hepatitis C
MSM (men who have sex with men)
PrEP
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:HIV pre‐exposure prophylaxis (PrEP) has been associated with incident hepatitis C virus (HCV) infection in men who have sex with men (MSM) due to decreased condom use. We examined rates of HCV among MSM and transgender women at high‐risk of HIV on PrEP in Southern California using data from two trials (NCT01761643 and NCT01781806). Five of 599 participants (0.84%, 95% CI, 0.27–1.93) had HCV antibodies detected at entry. Factors associated with HCV seropositivity included being older (p = .002) and lower education level (p < .001). HCV‐positive participants had no reported cases of sexually transmitted infection (rectal, urethral or pharyngeal gonorrhoea and/or chlamydia) at entry while HCV‐negative participants had a prevalence of 18% (95% CI, 15%–21%). There were no significant differences in substance use and sexual risk behaviour between HCV‐positive and HCV‐negative participants 1–3 months prior to entry. Among early PrEP adopters, incident HCV did not occur despite ongoing condomless intercourse. Screening intervals for HCV in MSM on PrEP should be led by a risk behaviour assessment.
Bibliography:Funding information
The manuscript was written at the University of California, San Diego. The data was collected from four academic medical centers including University of California, San Diego; University of Southern California; Harbor–University of California Los Angeles; and Long Beach Health Department.
Data for this analysis were collected as part of the California Collaborative Treatment Group 595 study supported by the California HIV/AIDS Research Program EI‐11‐SD‐005. PATH‐PrEP demonstration study was funded by the California HIV Research Program EI11‐LA‐002 with additional support from the Center for HIV Identification, Prevention, and Treatment (CHIPTS) NIMH grant MH58107; the UCLA Center for AIDS Research (CFAR) grant 5P30AI028697; and the National Center for Advancing Translational Sciences through UCLA CSTI Grant UL1TR000124. Gilead Sciences provided drug supply and additional support for some drug‐assay testing. RJL received honoraria and travel support from Gilead Sciences.
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1352-0504
1365-2893
DOI:10.1111/jvh.13678